On October 22, 2024, Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs. In connection with the merger, the combined company will be renamed Opus Genetics, Inc., effective October 23, 2024, and will trade on Nasdaq under the ticker symbol “IRD” effective October 24, 2024.

Wilson Sonsini Goodrich & Rosati advised Opus Genetics on IP matters related to the transaction. The Wilson Sonsini team includes Mike Hostetler, Derrick Rowe,  Sarah Cohen, Braden Anderson, and August Li.

For more information, please see the press release.